KIF20A regulated cancer via JAK-STAT3 and Hh signaling pathways. In colorectal cancer, increased KIF20A promoted cell proliferation through activated JAK-STAT3; in glioma, miR-876-3p suppressed KIF20A, inhibited JAK2-STAT3 signaling pathway; in hepatocellular carcinoma, KIF20A was a target of Hh signaling, Gli2 enhanced KIF20A by FoxM1, increased KIF20A promoted HCC growth and survival.